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Abstract
Background: Childhood ‘unusual experiences’ (such as hearing voices that others cannot, or suspicions of being
followed) are common, but can become more distressing during adolescence, especially for young people in contact
with Child and Adolescent Mental Health Services (CAMHS). Unusual experiences that are distressing or have adverse life
impact (UEDs) are associated with a range of current and future emotional, behavioural and mental health difficulties.
Recommendations for psychological intervention are based on evidence from adult studies, with some support from
small, pilot, child-specific evaluations. Research is needed to ensure that the recommendations suit children as well as
adults. The CUES+ study (Coping with Unusual ExperienceS for 12–18 year olds) aims to find out whether cognitive
behaviour therapy for UEDs (CBT-UED) is a helpful and cost-effective addition to usual community care for 12–18 year
olds presenting to United Kingdom National Health Service Child and Adolescent Mental Health Services in
four London boroughs.
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Methods: The CUES+ study is a randomised controlled trial comparing CBT-UED plus routine care to routine care
alone. CBT-UED comprises up to 16 sessions, including up to 12 individual and up to four family support meetings,
each lasting around 45–60 min, delivered weekly. The primary outcome is emotional distress. Secondary outcomes are
change in UEDs, risk events (self-harm, attendance at emergency services, other adverse events) and health economic
outcomes. Participants will be randomised in a 1:1 ratio after baseline assessment. Randomisation will be stratified by
borough and by severity of mental health presentation: ‘severe’ (an identified psychotic or bipolar disorder) or any
‘other’ condition. Outcomes will be assessed by a trained assessor blind to treatment condition at 0, 16 and 24 weeks.
Recruitment began in February, 2015 and is ongoing until the end of March, 2017.
Discussion: The CUES+ study will contribute to the currently limited child-specific evidence base for psychological
interventions for UEDs occurring in the context of psychosis or any other mental health presentation.
Trial registration: International Standard Randomised Controlled Trials, ID: ISRCTN21802136. Prospectively registered
on 12 January 2015. Protocol V3 31 August 2015 with screening amended.
Keywords: Child, psychotic-like experience (PLE), Community mental health, Cognitive behavioural therapy (CBT)
Background
Psychosis is a disabling and costly mental health condition
[1–6] with adverse social and functional outcomes, even
following an at-risk presentation [7, 8]. For adults with
psychosis, individual and family based cognitive behavioural
therapy/interventions (CBTp and FIp, respectively) are rec-
ommended by the United Kingdom National Institute for
Health and Care Excellence (UK NICE) [5, 6]. On the
strength of the adult evidence base, similar recommenda-
tions are made for children and young people under the
age of 18 years [4, 9]. The guidance extends the offer of
treatment to childhood presentations of psychotic-like, or
unusual experiences (such as hearing voices that others
cannot, or unfounded worries about being followed or
deliberately harmed) in the absence of a formal diag-
nosis of psychosis, or any other condition, when these
are accompanied by distress or adverse life impact
(UEDs).
Around 15% of young people in the general population
experience UEDs, with the rate increasing to around half
of young people referred to Child and Adolescent Mental
Health Services (CAMHS) with emotional and behavioural
problems [10–14]. The occurrence of non-distressing un-
usual experiences is higher in younger childhood, and fre-
quency generally decreases with age. However, as frequency
decreases, the likelihood of associated distress/adverse
impact increases [10, 15, 16]. Severity, distress and less ef-
fective coping skills predict a persisting trajectory [17].
UEDs have been associated with a range of poor mental
health outcomes and intervention is indicated to reduce
current distress and disability, with the potential to add-
itionally increase resilience and reduce future mental health
risk [12, 13, 18, 19]. However, for younger adolescents (aged
under 14 years), recent guidance suggests that the lack of
specificity of UEDs as a risk factor for psychosis contraindi-
cates explicitly preventative interventions [20, 21].
Cognitive behavioural models of psychosis assume a
continuum of experience, such that the same psycho-
logical processes are hypothesised to drive both the per-
sistence and severity of the cognitive, emotional and
behavioural difficulties that are characteristic of psychosis,
irrespective of whether or not they reach criteria for a diag-
nosis [22, 23]. Consistent with this, cognitive therapy has
been demonstrated to reduce transition to psychosis for
young people (usually aged 14 to 35 years) presenting with
an at-risk mental state [24]. However, non-transition is still
associated with difficulties in health and functioning, and
intervening earlier may offset the accumulation of dam-
aging personal, social and economic effects [7, 8, 25].
UK NICE guidance emphasises the need for trials in
children, to build a youth-specific evidence base, both
for early intervention with UEDs and for working with
young people with UEDs in the context of an identified
psychotic condition. Emerging evidence suggests that at
least some psychological targets of cognitive therapy are
common between adult psychosis and childhood UEDs
[11, 14, 26–29], supporting the use of similar therapeutic
strategies. However, research also suggests that standard
protocols are less effective for younger participants [30];
in a recent trial, for younger participants (mean age
16.5 years, range 14 to 30 years), unadapted CBTp per-
formed no better than generic support [31]. We have
shown, in pilot and case series work, that adapted, child-
specific cognitive behavioural interventions targeting
adolescent psychosis or childhood UEDs are feasible, ac-
ceptable, safe and potentially helpful [32–34]. This trial
will test our child-specific therapy adaptations, which in-
clude: shorter duration of sessions and of therapy as
needed; greater emphasis on behavioural change; explicit
connection with educational, social, familial, and par-
ticularly peer, context, and a focus on the developing
sense of self and identity. Given the importance of the
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familial context [35–38], and as the majority of young
people are living with an adult carer (usually an ex-
tended family member in a parental role), the interven-
tion includes up to four sessions of family work. The
role of the family environment in psychosis in adults has
been convincingly demonstrated [37]. Early evidence sug-
gests that parents of young people with UEDs, although
often unaware of their child’s unusual experiences, are
aware of associated emotional and behavioural difficulties
[10, 14, 36]. Parents of young people with UEDs experi-
ence higher levels of affective disturbance than the general
population, and difficulties in their relationship with their
child [36]. Associations between parental criticism, social
isolation, coping and affective disturbance, are consistent
with a cognitive model of caregiving in psychosis [36, 37].
There are suggestions that parental criticism can exacer-
bate UEDs [38]. Therefore, it is particularly important to
offer family support alongside individual interventions for
our target population.
Study aims
We plan to carry out a phase II interventional, rando-
mised controlled trial, to test the clinical and cost-
effectiveness of our adapted CBT for childhood UEDs
(CBT-UED), as an adjunct to routine care (treatment as
usual, TAU), in reducing distress in adolescents (aged
12–18 years) with UEDs in the context of psychosis or
any other presentation, in community CAMHS. The
CBT-UED intervention plus TAU condition will be com-
pared to TAU alone. Young people allocated to TAU will
be offered the CBT-UED intervention after completing
the final trial assessment.
The specific research questions to be addressed are:
1. Are clinical outcomes for young people with UEDs
improved by the addition of CBT-UED to routine
care?
2. Are the effect sizes comparable to those found in
the adult academic literature?
3. Is the intervention cost-effective?
Methods
Participants and setting
We aim to recruit 120 young people aged between 12
and 18 years, presenting to CAMHS in four London
boroughs served by the South London and Maudsley
National Health Service Foundation Trust: Southwark,
Lambeth, Croydon and Lewisham. The sample will be
transdiagnostic, and will include young people with a di-
agnosed or emergent psychosis, or any other presentation,
treated by the clinical team. However, all participants will
have unusual experiences in the form of positive psychotic
or psychotic-like phenomena, and associated distress/
adverse life impact.
Each borough service carries a caseload of around 500
young people, with around 60 new referrals per month
per borough and a workforce of around 70 community
mental health workers in total. The teams work with
young people whose presentation warrants secondary
mental health care; the usual criteria are risks of harm
to themselves or others. National incidence rates of
psychosis may be exceeded in the target services: a team
with 40–60 new referrals/month averages three psychosis
referrals/month. Population estimates and our recent
work indicate that at least an additional 25–50% of refer-
rals will have UEDs, in the absence of a psychosis diagno-
sis [10–14]. Based on approaching all new referrals, and
assuming a consent rate of 50%, we estimated a recruit-
ment rate of six young people/month.
Screening protocol
In order to participate in the CUES+ study, young
people need to present with unusual experiences with
accompanying distress and/or adverse life impact. Fol-
lowing our earlier pilot work with the target services
[34], borough teams routinely administer a measure of
unusual experiences (the Unusual Experiences Question-
naire, UEQ) [10, 14, 39, 40] with their standard assess-
ment battery. The UEQ has been shown to be a reliable
and valid measure of UEs for young people [12]. Re-
spondents rate each of nine UEs on a 3-point Conviction
scale: 0 (not true); 1 (somewhat true); 2 (certainly true);
endorsed UEs are rated for Frequency over the past
2 weeks: 0 (not at all); 1 (only once); 2 (2–4 times); 3
(5 + times); Distress (‘How much has it upset you?’)
and Adverse Impact (‘How much has it made things
hard at home or school?’), both rated: 0 (not at all); 1
(only a little); 2 (quite a lot); 3 (a great deal). Item totals
(ratings across dimensions of conviction, frequency, dis-
tress, impact, range 0–11), are summed to create a UE-
severity score, and, by selecting only those items where
distress or impact is rated > 0, a UED-severity score (0–99,
higher scores indicate greater severity). We have found
this screening procedure to be both feasible and accept-
able to young people and their families [34]. Screening is
important as UEDs are not otherwise routinely assessed in
community CAMHS, and, although parents and other in-
volved agencies may be aware of distress, or behavioural
problems, children tend not to report their UEDs unless
directly asked [10, 14]. Young people also routinely
complete a measure of childhood psychopathology (the
Strengths and Difficulties Questionnaire, SDQ) [41, 42].
We initially screened for young people rating any UE > 0
on UEQ conviction, who also had a score in the clinical
range (≥7) of the Emotional Problems subscale of the
SDQ (SDQ-E) to indicate current distress. However, early
recruitment figures (after 6 months of recruitment)
showed that 80% of young people endorsing unusual
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experiences but not meeting the SDQ-E distress criterion
were reporting distress and/or adverse impact associated
with the unusual experience, and expressing interest in
participating in the study. With the agreement of our fun-
ders, the clinical service, our Independent Trial Steering
Committee and our Research Ethics Committee (REC),
we therefore amended the criteria to also include en-
dorsing a UE, with self-rated distress or adverse im-
pact ≥ 0, with no requirement to meet the clinical
criterion of the SDQ-E. This was agreed sufficiently
close in time to the trial start (December, 2015) for
young people who had been excluded at the screening
stage to be recontacted regarding participation.
Inclusion and exclusion criteria
Inclusion criteria are: presenting to local CAMHS; current
unusual experience with associated distress and/or adverse
impact; aged 12–18 years; intending to be available for the
next 6 months in order to complete participation in the
study; sufficient English language ability for young people,
and parents as relevant, to be able to give informed con-
sent (or assent with parental consent), complete assess-
ment measures and participate in therapy, with interpreter
support as appropriate. Exclusion criteria are: having a
known learning disability (Intelligence Quotient, IQ < 70,
confirmed by the treating team); a UED occurring only
secondary to a known neurological condition (e.g. epilepsy
or brain injury); limited to states of acute intoxication/
withdrawal in the context of substance misuse.
Study design
CUES+ is a parallel-group RCT with random allocation
to one of two arms, comparing our active intervention
(CBT-UED+TAU) to routine care alone (TAU). Treat-
ment as usual (TAU) will be delivered without interference
in both conditions and includes care coordination, prac-
tical and emotional support for the young person and their
family, and medication as appropriate. We will record
what is delivered as routine care. Assessments will take
place at baseline (0 weeks), 16 weeks (post therapy) and
24 weeks (2 months post therapy). After 24 weeks, TAU
participants will be offered the intervention. Trained re-
search workers will complete assessments with parents
and young people. Baseline assessments will be carried
out prior to randomisation; 16- and 24-week assessments
will be arranged by the trial research worker, but carried
out by a different assessor who will be blind to treatment
allocation. Service and economic measures will be com-
pleted for the 6-month periods before and after baseline.
The study design is illustrated in Figs. 1 and 2 (Fig. 2
shows a modified version of the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
Figure for the trial).
Procedure
Recruitment
We will recruit directly from CAMHS community men-
tal health teams, starting in one borough, and extending
to the other boroughs as required to maintain the target
recruitment rate. Young people presenting with UEDs
(according to the screening measure) will be invited by
their team to find out more about the study, and, if
agreeing, will be contacted by the CUES+ study re-
searcher. The usual consent procedure for participants
aged under 16 years will be to secure parental consent
and child assent; and for those 16 years and over, to seek
the young person’s consent, and parental consent if the
child agrees to familial participation. This will be guided
by the clinical team’s assessment of the young person’s
capacity and other clinical issues impacting on consent
(e.g. whether Gillick competences [43] are met, man-
aging parental conflict and split care arrangements).
Young people reporting UEDs (and their families where
appropriate) will be offered the Information Sheet and
Consent/Assent Forms, with a follow-up call from the
research team within 2 to 4 weeks. Telephone conversa-
tions and meetings will take place as needed to discuss
the study; at least 24 h will elapse between receipt of the
study information and consent being sought for partici-
pation. Consenting young people and their families will
be offered a baseline assessment and will be randomised
only following completion of this.
Ethical approval
The study has been reviewed and given a favourable
opinion by the London Hampstead National Research
Ethics Service Committee (reference: 14/LO/1970).
Approval to recruit for the study in CAMHS in the
four boroughs of Southwark, Lambeth, Croydon and
Lewisham was granted centrally by the Joint Research
and Development Office of the South London and
Maudsley NHS Foundation Trust and the Institute of
Psychiatry, Psychology and Neuroscience (reference
R&D2015/003).
Intervention
The therapy will comprise up to 16 sessions, delivered
over 16 weeks, including up to 12 sessions of individual
CBT, adapted for adolescents, and up to four family sup-
port sessions. The intervention will be delivered in
addition to routine care (specialist care coordination,
practical and emotional support for the young person
and their family, and medication as appropriate), and
will be compared to routine care alone. After the 24-
week assessment, adolescents in the routine care condi-
tion will be offered the intervention.
Intervention will not ordinarily exceed a total of 16 ses-
sions (notwithstanding requirements to extend therapy to
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ensure safety and wellbeing), but may exceed 16 weeks of
delivery, as needed to accommodate, for example, holidays
and examination periods. The intervention content has
been developed from our earlier inpatient protocols for in-
dividual and family work with young people with psych-
osis [32], and adapted for young people with UEDs in the
general population [33] and in services for children with
emotional and behavioural problems [34]. Pilot work has
demonstrated feasibility, acceptability and potential help-
fulness of the intervention [32, 33]. Individual work fo-
cusses on developing a collaborative understanding of
UEDs, together with skills in affect regulation, managing
negative automatic thoughts, behavioural tests, dealing
with social difficulties and adverse life events, recognising
and compensating for cognitive biases, and a section on
taking the work forward and preventing future difficulties.
Where there has been trauma, therapists complete pre-
and post-therapy measures of event appraisals and
post-traumatic cognitions to aid therapy [44]. Therapy
is tailored to take account of the developmental stage
and presenting issues of the child/young person, with
an emphasis on identity formation, understanding of
the self in relation to the experience of psychosis/UEDs,
social inclusion and self-esteem. Therapy materials are de-
signed to be fun, interactive and engaging. Family support
is crucial when working with young people, and has been
requested by parents consulting on our studies. Family
work comprises recognition and understanding of the
child’s difficulties, sharing the intervention plan, and trou-
bleshooting any key familial difficulties.
Therapists
We will train and supervise CAMHS community thera-
pists to deliver the intervention. Therapists will contrib-
ute a full day or half a day per week, depending on the
agreement with their service, to see two to four trial
cases. The combined caseload across all therapists, given
the study recruitment targets, will be a maximum of 24
at any one time, allowing 60 young people to be seen
over a year. We will stagger the input of the therapists
to accommodate the growing caseload as the study
progresses.
Therapists will be trained to competence in delivery of
the manualised intervention and closely supervised by
the trial coordinator/supervisor. Therapy adherence will
be monitored by supervisors on an ongoing basis
through audio-recorded therapy sessions (for which we
will request service user consent). Adherence to the
manual will be checked by internal raters who are not
directly involved in the care of the participant (i.e. not
therapist or supervisor), using checklists of manual con-
tent incorporating general cognitive therapy skills, spe-
cific skills in working with UEDs, and appropriate
tailoring to the developmental stage and presentation of
each young person and family [32, 33]. An independent
expert will rate 10% of internally rated sessions: we will
Fig. 1 Coping with Unusual ExperienceS for 12–18 year olds (CUES+) study design. Key: UE Unusual experience, SDQ Strengths and
Difficulties Questionnaire [41, 42], TAU Treatment as usual (routine care)
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consider 90% rated as adherent to be acceptable. For the
duration of the trial, we will ensure that trained thera-
pists do not provide care coordination for young people
who are allocated to routine care. In each team, there is
an early-intervention-in-psychosis liaison worker, who
takes responsibility, irrespective of the trial, for ensuring
that routine care meets the needs of young people pre-
senting with psychosis.
Measures
Outcomes and timeline
Following informed consent from each participant, all
outcomes will be assessed by a trained study researcher.
Demographic/clinical characteristics (age, gender, ethni-
city, parent-reported developmental delays, family cir-
cumstances, diagnoses), brief cognitive functioning (word
reading, working memory and general intelligence) and
history of adverse life events and bullying will be assessed
at baseline [45–50]. Outcomes will be assessed at baseline
(0 weeks) then at 16 weeks and 24 weeks post randomisa-
tion, irrespective of treatment duration. Assessments will
not be completed more than 2 weeks after the planned
assessment time point. Outcomes and all measures are
listed in Table 1 and will be completed according to the
schedule in Fig. 2.
Primary outcome
The primary outcome will be distress at 16 weeks,
assessed using the SDQ-E, child-reported [41]. The SDQ
is well-validated and routinely used in local services for
youth up to 19 years [41, 42].
Secondary outcomes
Secondary outcomes will be child-reported UED se-
verity at 16 weeks, assessed using the self-report
UEQ [10, 14, 39]. Self-reported self-harm [45] and
adverse events including attendance at accident and
emergency services, and economic costs, including
quality-adjusted life years (QALYs) [51–54] will also
be assessed.
Coping with Unusual ExperienceS for 12-18 year olds (CUES+)        STUDY PERIOD 
Enrolment Allocation Post-allocation Close-out 
TIME POINT
Completed 
within four 
weeks  
Within two 
weeks of 
baseline,  
0 weeks
0-16 
weeks  
16-
weeks 
24-weeks 
ENROLMENT:       Routine eligibility screen X     
Informed consent/assent X     
Allocation  X    
INTERVENTION:                CBT-UED+TAU   X   
Treatment as usual (TAU)   X   
ASSESSMENTS:      Primary child outcome:  
Child-reported SDQ-E1
X   X 
Secondary child outcomes:
Child-reported UED severity2, self-harm3
X   X 
Secondary outcomes:
Adverse events and costs4,5
X (6 months 
preceding)
X (6 months 
preceding)
Other secondary child outcomes6-21 XX X
Secondary parent outcomes22-28 X   X 
Sessional & satisfaction (therapy only)29-32 X X 
Baseline only child assessment33-37 X     
Detailed trauma assessment (therapy only)38   X   
Fig. 2 Coping with Unusual ExperienceS for 12–18 year olds (CUES+): schedule of enrolment, interventions and assessments. Key: UED unusual
experience with distress, CBT cognitive behavioural therapy, 1Strengths and Difficulties Questionnaire (SDQ), Emotional Problems subscale [41, 42].
2Unusual Experiences Questionnaire (UEQ) – severity score [10, 14, 39]; 3from the Development and Wellbeing Scales (DAWBA) [45]. 4Child adaptation
of the Clinical Service Receipt Inventory [51]; 5EuroQol Health Questionnaire, youth version (EQ5D-Y) [52–54]. 6,7Parent- and child-reported full SDQ and
UEQ (including UEQ appraisals [68, 72]; 8,9researcher-reported functioning (Child Global Assessment Scale, Health of the Nation Outcome Scales for
Children and Adolescents) [86–88];10–12child- and parent-reported mood and behaviour (Revised Child Anxiety and Depression Scales [55]; Elevated
Mood Scales [56–58]; Me and My School, behavioural problems subscale [59]; 13–17child-reported trauma sequelae/emotion regulation (Difficulties in
Emotion Regulation Scale [60]; Adolescent Dissociative Experiences Scale [61]; Child Revised Impact of Events Scale-13 [62]; DAWBA eating disorder
screen [45]; Maudsley Addiction Profile [63]); 18Time budget measure of activities and peer relationships [64–66]; 19Beliefs about problems [69–72];
20Brief Core Schema Scale [27, 68]; 21Jumping to conclusions reasoning task [26, 73]; 22–24Parent caregiving experience and appraisals (Five Minute
Speech Sample [74]; Brief Illness Perception Questionnaire [36, 69]; Experience of Caregiving Inventory [78]; 25–28parent distress/wellbeing and coping
(Patient Health Questionnaire, Generalised Anxiety Disorder, Short Warwick-Edinburgh Mental Well-Being Scale, Brief COPE Scale with Confidante
Question [36, 75–78]. 29–32Short CHOICE with goals [84]; Session and Outcome Rating Scales [79–82]; service satisfaction [83]; 33demographics (age,
gender, ethnicity, parent-reported developmental delay); 34life events, bullying and brief trauma screen [69.70,45]; 35-37Wechsler Intelligence Scales for
Children – Fourth Edition (WISC-IV), Individual Attainment Test II (WIAT-II), Abbreviated Scale of Intelligence II (WASI-II) [48–50]. 38Children’s Post-
Traumatic Cognitions Inventory [44]
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Other clinical outcomes
We will also measure the cognitive, social, emotional
and behavioural therapy targets hypothesised to main-
tain UEDs. These will be assessed at 0, 16 and
24 weeks. Areas assessed include child self-reported
mood and behaviour problems (anxiety, depression, el-
evated mood, anger, hyperactivity, conduct disorder
and peer problems) [41, 42, 55–59]; child-reported
trauma sequelae, emotional regulation, substance mis-
use and eating disorders [45, 60–63]; activity levels, so-
cial support and sleep pattern [64–66], appraisals of
the self and others, UEDs and the presenting problem
[27, 28, 67–72]; and reasoning style [73]. Parent/carer
measures will be completed at 0 and 16 weeks, and will
include the 5-min speech sample to assess family rela-
tionships [74], and measures of parental affect, well-
being, caregiving experience, and coping [75–79], as
well as parental assessments of child mood and behav-
iour difficulties and UEDs [10, 14, 41, 42, 55–59]. Ses-
sional ratings will be used to measure the therapeutic
relationship, therapy progress and overall satisfaction
[80–85]. The Child Global Assessment Scale [86] and
Health of the Nation Outcome Scale for Children and
Adolescents [87, 88] will be completed at the 0-, 16-
and 24-week time points to assess general childhood
psychopathology and impact on functioning.
Table 1 Coping with Unusual ExperienceS for 12–18 year olds
(CUES+): list of measures
Measure Completed
By At
Primary outcome
1. Strengths and Difficulties Questionnaire-Emotional
Problems (SDQ-E) [41, 42]
1 0,1
Main secondary outcomes
2. Unusual Experiences Questionnaire – severity
score (UEQ) [10, 14, 39]
1 0,1
3. Self-harm (Development and Wellbeing Scales,
DAWBA) [45]
1 0,1
4. Child Clinical Service Receipt Inventory
(CSRI) [51]
2,3 − 1,2
5. EuroQol Health Questionnaire, youth
(EQ5D-Y) [52–54]
1,2 0,2
Other secondary child outcomes
6. Strengths and Difficulties Questionnaire
(SDQ) [41, 42]
1,2 0,1,2
7. Unusual Experiences Questionnaire
(UEQ) [10, 14, 39]
1,2 0,1,2
8. Child Global Assessment Scale
(C-GAS) [86]
3 0,1,2
9. Health of the Nation Outcome Scales for
Children and Adolescents (HoNOSCA) [87, 88]
3 0,1,2
10. Revised Child Anxiety and Depression
Scales (RCADS) [55]
1,2 0,1,2
11. Elevated Mood Scales [56–58] 1,2 0,1,2
12. Me and My School, behavioural problems
(M&MS) [59]
1,2 0,1,2
13. Difficulties in Emotion Regulation Scale
(DERS) [60]
1 0,1,2
14. Adolescent Dissociative Experiences Scale
(A-DES) [61]
1 0,1,2
15. Child Revised Impact of Events Scale
(CRIES-13) [62]
1 0,1,2
16. Eating disorder screen (DAWBA) [45] 1 0,1,2
17. Maudsley Addictions Profile (MAP) [63] 1 0,1,2
18. Time budget of activities and peer
relationships [64–66]
1 0,1,2
19. Beliefs about problems (BAP) [69–72] 1 0,1,2
20. Brief Core Schema Scale [27, 68] 1 0,1,2
21. Jumping to conclusions [26, 73] 1 0,1,2
Secondary parent outcomes
22. Five Minute Speech Sample (FMSS) [74] 2 0,1
23. Brief Illness Perception Questionnaire
(BIPQ) [36, 69]
2 0,1
24. Parental Experience of Caregiving Inventory
(ECI) [36, 78]
2 0,1
25. Depression: Patient Health Questionnaire
(PHQ-9) [75]
2 0,1
26. Generalised Anxiety Disorder (GAD-7) [76] 2 0,1
Table 1 Coping with Unusual ExperienceS for 12–18 year olds
(CUES+): list of measures (Continued)
Measure Completed
By At
27. Warwick-Edinburgh Mental Well-Being Scale
(WEMWBS) [77]
2 0,1
28. The Brief COPE Scale with Confidante
Question [36, 78]
2 0,1
Sessional and satisfaction (therapy only)
29. Short CHOICE with goals [84] 1,2 3
30 and 31. Session and outcome scales
(SRS & ORS) [79–82]
1,2 3
32. Service feedback scales [83] 1,2 2
Baseline only measures
33. Demographics and developmental history 1–3 0
32. Adverse Life Events, bullying and brief
trauma screen [45–47]
1 0
33–35. Word reading, digit span, vocabulary,
matrix reasoning [48–50].
1,3 0
Detailed trauma assessment (therapy only)
36. Children’s Post-Traumatic Cognitions
Inventory [44]
1,3 4
Key: Completed by: 1 = child; 2 = parent; 3 = researcher/therapist. Completed
at: − 1 = 6 months preceding baseline; 0 = 0 weeks, baseline; 1 = 16 weeks;
2 = 24 weeks; 3 = sessionally; 4 = early in therapy
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Economic outcomes
The main outcomes of interest will be unit changes in
distress levels measured by the SDQ-E (the primary out-
come of the RCT) [41, 42], and the QALY gain as mea-
sured with the EQ-5D-Y questionnaire at baseline
(0 weeks) and 24-week time points. The EQ-5D-Y is a
child version of the EQ-5D, which measures health-
related quality of life (HRQoL) in young populations
using an age-appropriate adjustment to the wording of
the original questionnaire [52–54]. The EQ-5D-Y con-
sists of five domains (mobility, self-care, usual activities
(e.g. work, study, housework, family or leisure activities),
pain/discomfort and anxiety/depression) and each is
rated 1 (no problems), 2 (some problems), or 3 (a lot of
problems) [54]. UK values will be applied to the distinct
health states derived from the EQ-5D-Y to estimate the
utility value for each participant at each time point, and
the area-under-the-curve methods will be used to calcu-
late the QALYs [53].
Service use and costs
Economic analysis will be conducted from the perspec-
tive of the national health care system and personal and
social services (NHS and PSS), but a wider perspective
including costs borne by the participants and their fam-
ilies will also be considered. Potential costs will include
lost education for children and lost time from work for
parents. The costs of lost education will be estimated using
a notional figure for the value of days in education. Inter-
vention costs will include the time spent by CAMHS com-
munity therapists to deliver the intervention, including
training and supervision costs. The Client Service Receipt
Inventory (CSRI) will be adapted and administered to rec-
ord participants’ use of health and social services for the 6-
month periods before and after baseline, respectively [51].
The CSRI has been developed by members of King’s
Health Economics and has been widely used in mental and
physical health economic evaluations. The data collected
through the CSRI will be used to calculate average service
costs and total costs of care. All unit costs will be derived
using routine data sources, such as the NHS reference
costs [89] and the Unit Costs of Health and Social Care
[90], as well as study-specific estimates where appropriate.
Medication use, such as name/type of drug, dosage levels
and frequencies, will be recorded and costs will be calcu-
lated based on prices from the British National Formulary
for Children [91] and the Prescription Cost Analysis [92].
From these, a mean cost per intervention and a mean cost
taking into account participant and carer costs will be
estimated.
Sample size
We will recruit 120 participants, randomly allocating 60
per group. From previous experience, we will allow for a
conservative loss-to-follow-up of approximately 33%
(85% follow-up achieved in an earlier pilot study [34].
With 45 successfully followed up in each group, we would
have 80% power to detect between group differences for
the smallest achieved effect sizes from previous studies of
cognitive therapy with young people (0.6 SD) using a two-
group t test with a 0.05 two-sided significance level. We
will have 90% power to detect effect sizes of 0.7 SD and
above. Our pilot work shows between group effect sizes of
0.6 in inpatients [32]. In practice, the power will be in-
creased by using a mixed (random)-effects model allowing
for baseline covariates including distress (rather than a
simple t test) to gain precision in the effect estimates, but
this increase is likely to be counteracted by allowing for
modest between-therapist variation.
Randomisation
Randomisation will be carried out after consent to par-
ticipate in the trial has been given and the baseline as-
sessment has been completed. Participants will be
randomised through an independent web-based service
provided by the UKCRC-registered King’s Clinical Trials
Unit (Reg. No. 053). The randomisation procedure will
employ random permuted blocks of random size, which
will maintain pre-randomisation allocation concealment.
We will stratify the randomisation lists by a Severe Men-
tal Illness (i.e. psychotic illness)/Other Mental Illness
factor, since this is an important prognostic factor. We
will also stratify by borough for logistical reasons, so that
treatment cases are equitably allocated across therapists.
Blinding procedure
We will not be able to blind participants to treatment
group. Similarly, the therapists cannot be blind to alloca-
tion as they will deliver the intervention. However, the
research workers completing outcome assessments will
be blinded to treatment allocation. Should they be acci-
dentally unblinded during the assessment, we will record
which outcomes were completed blind and allocate a
new assessor for any subsequent assessments. Post-
randomisation assessors will work separately from the
research and clinical teams to minimise the likelihood of
unblinding. We will ask research workers to guess the
allocation group for each participant at each assessment
as a test of the success of our efforts to maintain blind-
ness. We will report any instances of unblinding in sub-
sequent publications. The end of the trial will be defined
as the last follow-up assessment at 24 weeks. Routine-
care participants may continue to receive therapy be-
yond this point, and we will continue to collect sessional
measures, but this will be to inform therapy develop-
ment, implementation and training, rather than as part
of the outcomes of the study. Analyses will be completed
blind to allocation.
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Trial monitoring and oversight
We have established an Independent Trial Steering
Committee (ITSC), comprising an independent experi-
enced trialist as chair, a CAMHS researcher and clin-
ician who are not involved in the trial, the trial
statistician and two independent CAMHS carers or ser-
vice users. Sponsor and funder representatives will be in-
vited as required. We planned for the ITSC to convene
annually at 6, 18 and 30 months; meetings have taken
place at 9, 15, 21 and 27 months, with a final meeting
planned for 35 months. The ITSC will oversee the pro-
gress of the trial and will review any proposed protocol
changes. Any changes agreed by the ITSC will then be
put to all relevant regulatory bodies including the REC,
the sponsors and the funder. Approved changes will be
updated in the protocol and trial registry.
Data monitoring
Based on pilot studies, we do not anticipate risks to par-
ticipant safety as a direct result of the study and will not,
therefore, be conducting any interim data analysis and
will not convene a separate Data Monitoring Committee.
The trial may be prematurely discontinued by the spon-
sor, the chief investigator or the REC on the basis of
new safety information or for other reasons given by the
Ethics Committee or Trial Steering Committee.
If the trial is prematurely discontinued, active partici-
pants will be informed and no further participant data
will be collected. Arrangements will be made directly
with the local clinical service to ensure that the safety
and wellbeing of the young people and their families is
not compromised by this process.
Data management
We will use paper assessment packs and enter data into
electronic databases. Patient data will be pseudonymised
for the duration of the study and fully anonymised after
the retention period specified in institutional policies
(currently, 12 years) has passed. Fully identifiable per-
sonal details will be kept on paper in a locked filing cabi-
net in a locked or occupied office; on secure NHS
computers; and, encrypted, on password-protected com-
puters in the university. Pseudonymised data will be
stored on personal laptop computers, using recom-
mended secure encryption methods. All trial data will be
stored in line with the Data Protection Act [93].
Separate databases will be used for: (1) baseline demo-
graphics, (2) repeated clinical measures (separate data-
base for each time point), (3) child and parent measures,
(4) allocation, (5) sessional therapy measures, (6) feed-
back measures and (7) therapy delivery and adherence.
The allocation database will be accessible only to the
lead research worker (who will not conduct post-
baseline assessments) and the trial statistician until the
study is completed. Outcome assessments will be carried
out by researchers who do not have access to therapy or
feedback data. Data will be checked and cleaned against
original paper copies and a final database returned to
the statistician, who will combine with allocation data
for analysis.
Safety monitoring and adverse event reporting
We will monitor adverse events for all participants by
logging any reported by the participant or their network,
or the clinical or research team. We will also check the
medical record for unreported adverse events at each
time point (for the previous 6 months at baseline; since
the last assessment at 16 and 24 weeks). Events will be
rated for seriousness according to the impact on the par-
ticipant’s day-to-day life. The event will be considered to
be related to the trial if, in the view of the participant, a
member of their network, the clinical team or the re-
search team, it is reported to be related. The primary
concern in any report will be to work with the clinical
team and other emergency services as appropriate to en-
sure the participant’s safety. Serious adverse events that
are related to the trial will be discussed with the ITSC
and reported to the trial sponsor and the REC within
15 days.
Statistical analysis
In accordance with Consolidated Standards of Reporting
Trials (CONSORT) [94] principles, we will report all
participant flow in the study. Descriptive statistics will
be used to summarise assessments of feasibility and ac-
ceptability in terms of recruitment, dropout and com-
pleteness of therapy. The main efficacy analysis will be
via intention-to-treat with data from all participants in-
cluded in the analysis including those who do not
complete therapy. When completion of the full battery
of outcome measures is not possible, participants will be
offered the opportunity to complete the primary out-
come measure only, and as many of the main secondary
outcome measures as are tolerated, in person, by tele-
phone, or by email. Every effort will be made to follow
up all participants in both arms for research assess-
ments, and the analysis will use, where appropriate,
statistical techniques for handling missing data, deter-
mined by the extent and distribution of missing data,
and any identified demographic or baseline clinical pre-
dictors of missing data (age, gender, ethnicity, SDQ-E,
UED severity, Severe/Other Mental Illness, borough).
The primary hypothesis will be analysed using a linear
mixed model allowing for the baseline measurement of
SDQ-E and treatment assignment as fixed effects, with
SDQ-E at 4 months as the dependent variable. Therapist
effects will be modelled by including a random effect for
each therapist in the therapy arm, with the control-arm
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participants considered as being in individual clusters of
size 1. The use of a mixed (random)-effect models will
allow for estimation of the intra-cluster correlation coef-
ficient, a measure of the proportion of variance in out-
come because of therapist effects, which can be used in
future applications; no estimate of this is currently avail-
able. Secondary outcome measures (excluding economic
outcomes) will be analysed using the same approach.
Health economic analysis
Health economic analysis will be carried out to compare
the service use, costs and cost-effectiveness of cognitive be-
havioural therapy (CBT-UED) as adjunct to the TAU inter-
vention in young people (aged 12–18 years) with UEDs.
Economic analyses will include a cost-effectiveness
and a cost-utility analysis with the respective outcomes
being; the cost per one unit change in the SDQ-E scores
and the cost per QALY gained. Analyses will be carried
out primarily on an intention-to-treat basis although
other exploratory analyses, such as per-protocol, may
also be considered. Data will be analysed at the end of
the study; there are no planned interim analyses. Mul-
tiple regression methods will be applied to estimate
mean differences in costs and effects, using baseline and
follow-up data as the dependent variables and the group
identifier as an independent variable. Data with missing
observations due to loss to follow-up will be examined
to determine both its extent and whether it is missing at
random or is informative. If data are missing to a suffi-
cient extent, the use of appropriate multiple imputation
techniques will be considered.
Bootstrap analysis
To account for the likely skewed distribution of cost
data, the non-parametric bootstrap method will be used
to make cost comparisons between the two groups [95].
Bootstrapping involves repeatedly estimating the incre-
mental cost-effectiveness ratio to account for the uncer-
tainty surrounding the estimates of costs and effects.
Likewise, using the net benefit approach, estimates of
the proportion of iterations in which the intervention of
interest has the maximum expected net benefit (NB), or
equivalently, a positive incremental NB will be deter-
mined for a range of willingness-to-pay thresholds. The
estimates will be produced by repeatedly sampling with
replacement from the existing trial population [96]. The
results of the bootstrap analyses will be plotted on cost-
effectiveness planes (CEPs) and will be used to estimate
cost-effectiveness acceptability curves (CEACs), which
show the probability of the intervention to be cost-
effective subject to a range of thresholds that society
would be willing to pay for a unit improvement in the
health outcome (e.g. QALYs) [97]. However, using
change in distress levels (SDQ scores) as a measure of
health status makes a meaningful interpretation of the
CEACs difficult, as acceptance thresholds do not apply.
In this case, thresholds at which the intervention has,
e.g. above 60% likelihood of being cost-effective, will be
explored.
Sensitivity analysis
Both cost-effectiveness and cost-utility analyses will in-
clude deterministic sensitivity analyses around the inter-
vention costs, the costs from lost work (for parents) and
lost education (for children) by varying the initial figures
within plausible ranges. This will help increase the level
of confidence about potentially key drivers of the ana-
lyses and will provide insights into the systematic inclu-
sion of such costs in the evaluation of interventions
targeted to children.
Discussion
We have adhered to SPIRIT (Standard Protocol Items:
Recommendations for Interventional Trials) [98, 99]
guidance in devising and reporting our protocol (Fig. 2;
SPIRIT Checklist with Information Sheets and Consent
Forms for young person and parent participants are in-
cluded as Additional files 1 and 2). The trial is funded
until the end of September, 2017, and results will be
available during 2018. If the intervention shows effects,
we will have demonstrated both the feasibility and the
usefulness of training CAMHS clinicians to provide spe-
cialised interventions for young people with UEDs. The
study will be the first youth-specific trial of CBTp, and,
should the therapy be successful, will support implemen-
tation of government recommendations in CAMHS, as
well as informing therapist training models, and future
clinical guidance. Economic evidence will potentially in-
form commissioning, service provision and policy, in-
cluding workforce development. Findings will be limited
by the size of the study, it being the first of its kind, and
its location in a single, specialist organisation. Replication
on a wider scale, across multiple sites, will be required,
We plan to disseminate findings via local academic and
clinical networks, through conference presentation and
publication. Authorship will be restricted to those making
a substantial contribution to the specific publication. We
will continue to implement the work locally. and apply for
funding for a larger, multisite study to investigate the po-
tential value of implementation across settings.
Status
Participants began to enter the trial in February 2015.
The first participant was randomised on 4 March 2015;
111 participants (of a target of 120) have been rando-
mised to date. Recruitment will continue until 31 March
2017. Final primary outcome data at 16 weeks will be
collected by the end of July 2017.
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Additional files
Additional file 1: Coping with unusual experiences for 12–18 year olds
(CUES+): SPIRIT Checklist. (DOC 122 kb)
Additional file 2: Coping with unusual experiences for 12–18 year olds
(CUES+): Participant Information Sheets and Consent/Assent Forms.
(DOC 4408 kb)
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